{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:07:46Z","timestamp":1767845266387,"version":"3.49.0"},"reference-count":20,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2,1]]},"abstract":"<jats:sec>\n                  <jats:title>BACKGROUND:<\/jats:title>\n                  <jats:p>Meningococcal conjugate vaccines were licensed beginning in 2005 on the basis of serologic end points and recommended for use in adolescents. A single dose at age 11 to 12 years was expected to provide protection through late adolescence. We conducted a case-control evaluation of vaccine effectiveness (VE) and duration of protection of a meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine (MenACWY-D).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS:<\/jats:title>\n                  <jats:p>Cases of culture- or polymerase chain reaction-confirmed serogroup A, C, W, and Y meningococcal disease among adolescents were identified through meningococcal disease surveillance sites in the United States from January 1, 2006, through August 31, 2013. Attempts were made to enroll 4 friend and school controls per case. VE was calculated using the generalized estimating equation, controlling for underlying medical conditions and smoking.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS:<\/jats:title>\n                  <jats:p>Serogroup C accounted for 88 (49%), serogroup Y 80 (44%), and serogroup W 13 (7%) of enrolled cases. Thirty-six (20%) cases and 87 (44%) controls received MenACWY-D. The overall VE estimate 0 to 8 years postvaccination was 69% (51% to 80%); VE was 79% (49% to 91%) at &amp;lt;1 year, 69% (44% to 83%) at 1 to &amp;lt;3 years, and 61% (25% to 79%) at 3 to &amp;lt;8 years. VE was 77% (57% to 88%) against serogroup C and 51% (1% to 76%) against serogroup Y.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS:<\/jats:title>\n                  <jats:p>MenACWY-D was effective in the first year after vaccination but effectiveness waned 3 to &amp;lt;8 years postvaccination. The estimates of VE from this evaluation informed the Advisory Committee on Immunization Practices in its decision to add a booster dose of MenACWY.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2016-2193","type":"journal-article","created":{"date-parts":[[2017,1,18]],"date-time":"2017-01-18T10:10:24Z","timestamp":1484734224000},"source":"Crossref","is-referenced-by-count":66,"title":["Effectiveness and Duration of Protection of One Dose of a Meningococcal Conjugate Vaccine"],"prefix":"10.1542","volume":"139","author":[{"given":"Amanda C.","family":"Cohn","sequence":"first","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica R.","family":"MacNeil","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee H.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Lynfield","sequence":"additional","affiliation":[{"name":"Minnesota Department of Health, St Paul, Minnesota;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Reingold","sequence":"additional","affiliation":[{"name":"School of Public Health, University of California, Berkley, California; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Schaffner","sequence":"additional","affiliation":[{"name":"Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth R.","family":"Zell","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Plikaytis","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy E.","family":"Messonnier","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Active Bacterial Core Surveillance (ABCs) Team and MeningNet Surveillance Partners","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2017,2,1]]},"reference":[{"key":"2021121020324382600_B1","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"issue":"53","key":"2021121020324382600_B2","first-page":"1","article-title":"Summary of notifiable diseases--United States, 2012.","volume":"61","author":"Adams","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"2021121020324382600_B3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","article-title":"Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease.","volume":"50","author":"Cohn","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2021121020324382600_B4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1128\/jcm.32.2.323-330.1994","article-title":"Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population.","volume":"32","author":"Caugant","year":"1994","journal-title":"J Clin Microbiol"},{"issue":"12","key":"2021121020324382600_B5","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis.","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"2021121020324382600_B6","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1093\/infdis\/jiu679","article-title":"Meningococcal carriage among Georgia and Maryland high school students.","volume":"211","author":"Harrison","year":"2015","journal-title":"J Infect Dis"},{"key":"2021121020324382600_B7","author":"MacNeil","year":"2011"},{"issue":"1","key":"2021121020324382600_B8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3201\/eid0701.010114","article-title":"Active bacterial core surveillance of the emerging infections program network.","volume":"7","author":"Schuchat","year":"2001","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"2021121020324382600_B9","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1128\/JCM.42.1.320-328.2004","article-title":"Use of real-time PCR to resolve slide agglutination discrepancies in serogroup identification of Neisseria meningitidis.","volume":"42","author":"Mothershed","year":"2004","journal-title":"J Clin Microbiol"},{"issue":"4","key":"2021121020324382600_B10","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/EDE.0b013e318064630a","article-title":"Analysis of matched case-control data with incomplete strata: applying longitudinal approaches.","volume":"18","author":"Lin","year":"2007","journal-title":"Epidemiology"},{"issue":"29","key":"2021121020324382600_B11","first-page":"625","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years\u2013United States, 2013","volume":"63","author":"Elam-Evans","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021121020324382600_B12","author":"Gill","year":"2014"},{"issue":"11","key":"2021121020324382600_B13","doi-asserted-by":"crossref","first-page":"881","DOI":"10.4161\/hv.6.11.12849","article-title":"Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo\u00ae) or Menactra\u00ae among healthy adolescents.","volume":"6","author":"Gill","year":"2010","journal-title":"Hum Vaccin"},{"issue":"30","key":"2021121020324382600_B14","first-page":"1018","article-title":"Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease--Advisory Committee on Immunization Practices (ACIP), 2011.","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"33","key":"2021121020324382600_B15","doi-asserted-by":"crossref","first-page":"850","DOI":"10.15585\/mmwr.mm6533a4","article-title":"National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2015.","volume":"65","author":"Reagan-Steiner","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"2021121020324382600_B16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nri2494","article-title":"Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.","volume":"9","author":"Pollard","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"2 pt 1","key":"2021121020324382600_B17","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0022-3476(05)80424-X","article-title":"Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines.","volume":"120","author":"Decker","year":"1992","journal-title":"J Pediatr"},{"issue":"9431","key":"2021121020324382600_B18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet"},{"issue":"22","key":"2021121020324382600_B19","first-page":"608","article-title":"Use of Serogroup B Meningococcal Vaccines in Persons Aged \u226510 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015.","volume":"64","author":"Folaranmi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"41","key":"2021121020324382600_B20","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.15585\/mmwr.mm6441a3","article-title":"Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015.","volume":"64","author":"MacNeil","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2016-2193\/1062301\/peds_20162193.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2016-2193\/1062301\/peds_20162193.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T06:30:19Z","timestamp":1639204219000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/139\/2\/e20162193\/60323\/Effectiveness-and-Duration-of-Protection-of-One"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,1]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2,1]]},"published-print":{"date-parts":[[2017,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2016-2193","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,1]]},"article-number":"e20162193"}}